logo
The Four Stages of Chronic Obstructive Pulmonary Disease (COPD)

The Four Stages of Chronic Obstructive Pulmonary Disease (COPD)

Health Line02-07-2025
Key takeaways
COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function.
The GOLD system previously classified COPD from stages 1 to 4 based on lung capacity as measured by a spirometry test. New guidelines now combine spirometry results with symptom severity to assess risk and determine staging.
Quitting smoking and avoiding secondhand smoke after receiving a diagnosis of COPD can improve your life expectancy and outlook.
People with COPD often have trouble breathing, a persistent cough, and shortness of breath. COPD can be subdivided into stages or grades, depending on how far it has progressed.
It is most common in smokers and people over the age of 40.
Keep reading to learn about the four stages of COPD. We'll discuss the symptoms you can expect at each stage and potential treatment options.
What is the GOLD system for categorizing COPD severity?
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a program started by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO). Countries around the world use its guidelines and recommendations for diagnosing and treating COPD.
The GOLD system previously classified COPD from stages 1 to 4 solely based on your lung capacity measured by a spirometry test. But the newest GOLD guidelines combine your spirometry results with subjective measures of your symptom severity to determine your level of risk based on their ABCD rubric.
A spirometer test involves exhaling into a machine called a spirometer. The machine measures how hard and quickly you can exhale.
Your doctor examines two numbers in your results: your force vital capacity (FVC) and your force expiratory volume in one second (FEV1). Your FVC is the total amount of air you can breathe out and FEV1 is the amount you breathe out in one second. A ratio of your FEV1/FVC needs to be less than 0.7 for a diagnosis of COPD.
Doctors grade your spirometry results from grade 1 (least severe) to grade 4 (most severe). In the old system, these grades correlate with stage 1 to stage 4 COPD.
Doctors determine the severity of your symptoms using either the British Medical Research Council (mMRC) questionnaire or the COPD Assessment Test (CAT).
Stage 1: Early
Stage 1 COPD is considered mild. At this stage, you may not be aware that you have anything wrong with your lung function. A doctor assigns you with grade 1 COPD if your FEV1 is between 80 and 100% of your predicted value.
Symptoms
If you score grade 1 on your spirometry test, you may not have any noticeable symptoms. If you do have symptoms, you may develop a cough and increased mucus production. You may mistake the early stages of COPD for the flu.
Treatment
With stage 1 COPD, your doctor may recommend a bronchodilator medication to open up the airways in your lungs. These medications are usually taken through an inhaler or nebulizer.
Your doctor may also recommend getting flu, COVID-19, and pneumonia vaccines to prevent illnesses that may worsen your respiratory symptoms.
Changing lifestyle habits that led to the development of COPD can potentially help slow the progression of your COPD.
Most people with COPD have a history of smoking. Quitting smoking and avoiding secondhand smoke are two of the most important things you can do to improve your outlook with COPD.
Stage 2: Mild
Your COPD is considered to be stage 2 when your FEV1 drops to 50 to 79% of your predicted value.
Symptoms
During stage 2, your symptoms worsen from stage 1. Your coughing and mucus production may become more severe, and you may experience shortness of breath when walking or exercising. Typically, it's in this stage that people realize that something is wrong and seek medical attention from a doctor.
Treatment
You may be given bronchodilator medication to increase airflow to your lungs.
Your doctor may recommend pulmonary rehabilitation, a program designed to increase your awareness about your condition. It's usually offered as a group class where you learn how to manage your condition better.
If you have a flare-up of symptoms, you may need to take steroids or oxygen.
Stage 3: Severe
By the time you reach stage 3, COPD is considered severe, and your forced expiratory volume is between 30 to 50 percent of your predicted value. You may have trouble catching your breath doing household chores and may not be able to leave your house.
Symptoms
By stage 3, you may get more frequent flare-ups, and your shortness of breath and coughing typically get worse. You will likely find you get tired easier than before.
Other potential symptoms can include:
Treatment
The treatment options for stage 3 COPD are similar to stage 2. You're more likely to need oxygen therapy at this stage.
Stage 4: Very severe
Stage 4 is considered very severe. Your forced expiratory volume is less than 30% of your normal value, and your blood oxygen levels are also low. You're at risk of developing COPD complications like heart or lung failure.
Symptoms
By stage 4, you'll likely have frequent flare-ups that can be potentially fatal. You may have trouble breathing even when you're resting.
Treatment
Treatment options during stage 4 are similar to the previous stages. Your doctor may also recommend lung surgery to improve breathing. Surgical options include:
lung transplant
lung volume reduction surgery
bullectomy
Is there an end stage to COPD?
A grade 4 score on your spirometry test is the highest grade you can receive. This category is also sometimes referred to as end stage COPD.
For many people at this stage, quality of life is usually fairly low, and symptom flare-ups can be fatal.
What is the life expectancy of someone with COPD?
Having COPD lowers your life expectancy. However, the amount that it affects your life expectancy depends on many factors, such as how far your COPD has progressed and whether you quit smoking or change the other lifestyle habits that lead to COPD.
An older 2009 study found that COPD led to a small reduction in life span for people who have never smoked, but a larger life span decrease for people who currently smoke or smoked in the past.
According to the researchers, a 65-year-old man who smokes would lose 3.5 years from their life expectancy for smoking, plus the following values for having COPD:
Stage 1: 0.3 years
Stage 2: 2.2 years
Stage 3 or 4: 5.8 years
For former smokers, the reductions are:
Stage 1: 1.4 years
Stage 2, 3, or 4: 5.6 years
For somebody who never smoked, the reductions are:
Stage 2: 0.7 years
Stage 3 or 4: 1.3 years
In a 2017 study, researchers followed a group of long-term smokers with COPD for 5 years. They found that participants who had died before a 5-year follow-up had a longer average smoking time and a lower prevalence of quitting smoking. The researchers concluded that smoking time may be related to COPD mortality rate, and quitting smoking has the largest potential to influence COPD outlook.
A 2020 study of 532 people with COPD at a hospital in Taiwan suggests that loss of life years can vary based on a person's GOLD stage:
GOLD stage 1: no reduction
GOLD stage 2: 6.2 years
GOLD stage 3: 9.3 years
GOLD stage 4: 9.4 years
This study did not distinguish by smoking history.
Can you prevent COPD from progressing?
COPD can't be reversed, and it's currently not possible to stop the progression of your COPD completely. You can help slow the progression of COPD as much as possible by working with your doctor and following a proper treatment program.
Living with COPD
No matter how far your COPD has progressed, it's important to change the lifestyle habits that caused your COPD in the first place. The most important thing you can do is quit smoking. If you don't quit, you'll continue to damage your lungs, and your COPD will progress quicker than it would otherwise.
Eating a nutrient-rich eating plan filled with plenty of vegetables, healthy fats, protein, and unprocessed foods may help you manage your symptoms and maintain a healthy weight. Eating foods that cause bloating, like apricots or peaches, may worsen breathing problems in some people.
Regular exercise may help decrease symptoms of COPD by strengthening your respiratory muscles and improving your cardiovascular health. Your doctor may be able to suggest exercise that is safe for you.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Man took diet advice from ChatGPT, ended up hospitalized with hallucinations
Man took diet advice from ChatGPT, ended up hospitalized with hallucinations

Yahoo

timean hour ago

  • Yahoo

Man took diet advice from ChatGPT, ended up hospitalized with hallucinations

A man was hospitalized for weeks and suffered from hallucinations after poisoning himself based on dietary advice from ChatGPT. A case study published on Aug. 5 in the Annals of Internal Medicine, an academic journal, states the 60-year-old man decided he wanted to eliminate salt from his diet completely. To do so, he asked ChatGPT for an alternative to salt, or sodium chloride, to which the AI chatbot suggested sodium bromide, a compound historically used in pharmaceuticals and manufacturing. While the journal noted that doctors were unable to review the original AI chat logs and that the bot likely suggested the substitution for another purpose, such as cleaning, the man purchased sodium bromide and used it in place of table salt for three months. As a result, he ended up in the ER with paranoid delusions, despite having no history of mental health problems. Convinced that his neighbor was poisoning him, the man was reluctant to even accept water from the hospital, despite reporting extreme thirst. He continued to experience increased paranoia, as well as auditory and visual hallucinations, eventually landing him an involuntary psychiatric hold after he tried to escape during treatment. What was happening to the man? Doctors determined that the man was suffering from bromide toxicity (or bromism), which can result in neurological and psychiatric symptoms, as well as others experienced by the man, including acne and cherry angiomas (bumps on the skin), fatigue, insomnia, subtle ataxia (clumsiness) and polydipsia (excessive thirst). Other symptoms of bromism can include nausea and vomiting, diarrhea, tremors or seizures, drowsiness, headache, weakness, weight loss, kidney damage, respiratory failure and coma, according to iCliniq. Bromism was once far more common due to bromide salts having been used in everyday products. In the early 20th Century, it was used in over-the-counter medications, often resulting in neuropsychiatric and dermatological symptoms, according to the study's authors. Incidents of such poisoning saw a sharp decline when the Food and Drug Administration phased out the use of bromides in pharmaceuticals between the mid 70s and late 1980s. The man was treated at the hospital for three weeks, over which time his symptoms progressively improved. USA TODAY reached out to OpenAI, the maker of ChatGPT, for comment on Wednesday, Aug. 13, but has not received a response. The company provided Fox News Digital with a statement, saying, "Our terms say that ChatGPT is not intended for use in the treatment of any health condition, and is not a substitute for professional advice. We have safety teams working on reducing risks and have trained our AI systems to encourage people to seek professional guidance." AI can 'fuel the spread of misinformation,' doctors say Doctors involved in the case study said they suspected that the patient had used ChatGPT version 3.5 or 4.0, the former of which they tested in an attempt to replicate the answers the man received. While the study's authors noted that they couldn't know exactly what the man was told without the original chat log, they did receive a suggestion for bromide as a replacement for chloride in their tests. "Though the reply stated that context matters, it did not provide a specific health warning, nor did it inquire about why we wanted to know, as we presume a medical professional would do," said study authors Dr. Audrey Eichenberger, Dr. Stephen Thielke and Dr. Adam Van Buskirk. AI carries the risk of providing information like this without context, according to the doctors. For example, it is unlikely that a medical expert would have mentioned sodium bromide at all if a patient asked for a salt substitute. "Thus, it is important to consider that ChatGPT and other AI systems can generate scientific inaccuracies, lack the ability to critically discuss results, and ultimately fuel the spread of misinformation," according to the study. This article originally appeared on USA TODAY: Man hospitalized after taking ChatGPT diet advice, study says Solve the daily Crossword

Provident Healthcare Partners Advises OrthoNY on its Partnership with Zenyth Partners
Provident Healthcare Partners Advises OrthoNY on its Partnership with Zenyth Partners

Yahoo

time2 hours ago

  • Yahoo

Provident Healthcare Partners Advises OrthoNY on its Partnership with Zenyth Partners

BOSTON and NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Provident Healthcare Partners ("Provident"), a leading healthcare investment banking firm, announced it has advised OrthoNY in a recapitalization with Zenyth Partners ("Zenyth") to form Evolve Orthopedic Partners ("Evolve"). OrthoNY is a leading orthopedic care provider in the Capital Region of New York with 43 physicians and 84 total providers, dedicated to providing high quality musculoskeletal care to patients across its eight clinics and three ambulatory surgery centers. Provident's deal team was led by Managing Directors Eric Major and Scott Davis. McGuireWoods LLP served as legal counsel to ONY, and Alston & Bird LLP served as legal counsel to Zenyth. "Provident brought the clarity, confidence and expertise we needed to navigate this complex process. From day one, they took the time to understand our goals, challenge our thinking and keep us focused on the bigger picture," said David Fitzgerald, CEO of OrthoNY. "Their commitment never wavered, from early calls to late-night check-ins, they were true partners every step of the way. We're grateful to have had their guidance," added Dr. Lee Kaback, Vice President of OrthoNY. "They understood what makes OrthoNY unique and helped us protect and strengthen that as we look toward the future." "The OrthoNY leadership team engaged with Provident under the vision of developing a new regionally focused musculoskeletal platform with a partner. Zenyth Partners is a perfect match given their dedicated thesis in the MSK sector and experience developing other provider platforms in the Northeast region. We look forward to following the continued success of Evolve," noted Major. About OrthoNYOrthoNY is a leading orthopedic practice providing comprehensive musculoskeletal care, including surgical and non-surgical treatments, across multiple locations in Upstate New York. The Company is recognized for its expertise in joint replacement, sports medicine, spine care, pain management and more. With a strong reputation for clinical excellence and compassionate care, OrthoNY continues to be a top choice for orthopedic services in the region. For more information, visit About Zenyth PartnersZenyth Partners is an operationally focused investment firm focused exclusively on building leading healthcare companies. Zenyth partners with entrepreneurs, clinicians, and operators that share similar values, creating differentiated healthcare organizations that support patients, providers, payors, and the community at large. For more information, visit About Provident Healthcare PartnersProvident is a leading healthcare investment banking firm specializing in merger and acquisition advisory, strategic planning, and capital formation services for healthcare companies. The firm has a comprehensive knowledge of market sectors and specialties, including orthopedics. Provident also has unsurpassed experience and insight into the M&A process, which includes working with a multitude of investors such as private equity firms and strategic consolidators. For additional information, visit or follow Provident on LinkedIn. Contact: Provident Healthcare PartnersEric Major 617-226-4212 emajor@ View original content to download multimedia: SOURCE Provident Healthcare Partners LLC

Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains

Yahoo

time2 hours ago

  • Yahoo

Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains

BOULDER, CO / / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its HOCl-based diaper rash product for infants and children into large retailers in the United States. The antimicrobial hydrogel is being marketed and sold through Sonoma's U.S.-based distribution partner. The diaper rash product is currently carried in 3,600 Walmart stores, and certain large grocery chains. "We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels," said Amy Trombly, CEO of Sonoma. "We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations." About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Website: us on LinkedIn: us on Instagram: us on Facebook: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store